NEW YORK, Jan. 20, 2023 (GLOBE NEWSWIRE) — Juan MonteverdeFounder and managing partner of the collective law firm Monteverde & Associates PC (the “M&A Class Firm”), a nationally rated investment firm top 50 in the 2018-2021 ISS Securities Class Action Services Report and is headquartered at the Empire State Building in New York City, examined:

• Angion Biomedia Corp. (NASDAQ: ANG), in relation to the proposed merger with Elicio Therapeutics. Under the terms of the agreement, Elicio shareholders are expected to receive new shares in ANGN, with ANGN shareholders expected to own approximately 34.5% of the combined company. Click here for more information: https://www.monteverdelaw.com/case/angion-biomedia-corp. It’s free and there are no costs or obligations to you.
  
• Concert Pharmaceuticals, Inc. (NASDAQ: CNCE), in relation to the proposed acquisition by Sun Pharmaceutical Industries Limited. Under the terms of the tender offer, CNCE shareholders are expected to receive $8.00 in cash and a non-tradable CVR worth $3.50 in cash for each share they own. Click here for more information: https://www.monteverdelaw.com/case/concert-pharmaceuticals-inc. It’s free and there are no costs or obligations to you.
  
• Vallon Pharmaceuticals, Inc. (NASDAQ: VLON)regarding the proposed merger with GRI Bio, Inc. Under the terms of the agreement, VLON shareholders are expected to own approximately 17% of the combined company. Click here for more information: https://www.monteverdelaw.com/case/vallon-pharmaceuticals-inc. It’s free and there are no costs or obligations to you.
  

About Monteverde & Associates PC

We are a national securities and consumer class action law firm that has recovered millions of dollars for shareholders and is committed to investor protection and consumers from corporate wrongdoing. Attorneys at Monteverde & Associates have extensive experience litigating mergers and acquisitions and securities class actions, protecting investors by…